{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:31:07Z","timestamp":1790771467765,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.revmed.2016.02.016","type":"journal-article","created":{"date-parts":[[2016,3,25]],"date-time":"2016-03-25T10:00:55Z","timestamp":1458900055000},"page":"113-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Role of B cells in the pathogenesis of systemic sclerosis"],"prefix":"10.1016","volume":"38","author":[{"given":"S.","family":"Sanges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Guerrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lef\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Labalette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Forestier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Sobanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8624-6551","authenticated-orcid":false,"given":"J.","family":"Corli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hauspie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jendoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-Y.","family":"Hatron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dubucquoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2016.02.016_bib0615","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12016-010-8198-y","article-title":"Diagnosis and classification of systemic sclerosis","volume":"40","author":"Hachulla","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0620","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1136\/annrheumdis-2012-202489","article-title":"Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era","volume":"72","author":"Launay","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.02.016_bib0625","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/art.38029","article-title":"Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis: survival and prognosis in SSc-associated pulmonary hypertension","volume":"65","author":"Lef\u00e8vre","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib0630","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.revmed.2011.02.004","article-title":"Complaints, needs of patients with systemic sclerosis: a better understanding for a better care","volume":"32","author":"Morell-Dubois","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2016.02.016_bib0635","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0755-4982(06)74924-7","article-title":"Physiopathologie de la scl\u00e9rodermie syst\u00e9mique\u00a0: \u00e9tat des lieux sur une affection aux multiples facettes","volume":"35","author":"Servettaz","year":"2006","journal-title":"Presse Med"},{"key":"10.1016\/j.revmed.2016.02.016_bib0640","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib0645","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/ar2965","article-title":"B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial","volume":"12","author":"Bosello","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2016.02.016_bib0650","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2016.02.016_bib0655","doi-asserted-by":"crossref","first-page":"12319","DOI":"10.1073\/pnas.1635114100","article-title":"Systemic and cell type-specific gene expression patterns in scleroderma skin","volume":"100","author":"Whitfield","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl. 91","key":"10.1016\/j.revmed.2016.02.016_bib0660","first-page":"160","article-title":"Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab","volume":"33","author":"Fraticelli","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0665","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/jcp.2004.019224","article-title":"Alterations of mononuclear inflammatory cells, CD4\/CD8+ T cells, interleukin 1\u03b2, and tumour necrosis factor \u03b1 in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis","volume":"58","author":"Hussein","year":"2005","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0670","doi-asserted-by":"crossref","first-page":"e2696","DOI":"10.1371\/journal.pone.0002696","article-title":"Molecular subsets in the gene expression signatures of scleroderma skin","volume":"3","author":"Milano","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.revmed.2016.02.016_bib0675","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/jid.2011.472","article-title":"Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies","volume":"132","author":"Pendergrass","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0680","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/art.22847","article-title":"B cell infiltration in systemic sclerosis\u2013associated interstitial lung disease","volume":"56","author":"Lafyatis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib0685","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1752-699X.2010.00228.x","article-title":"Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease","volume":"6","author":"De Santis","year":"2012","journal-title":"Clin Respir J"},{"key":"10.1016\/j.revmed.2016.02.016_bib0690","first-page":"693","article-title":"NK cell populations in collagen vascular disease","volume":"30","author":"Papakosta","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0695","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1002\/art.23806","article-title":"Endothelial\/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis","volume":"58","author":"Manetti","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib0700","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bjd.12411","article-title":"CXCL13 and B cell activating factor as putative biomarkers in systemic sclerosis","volume":"169","author":"Wutte","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0705","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/art.38023","article-title":"CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis: CCL19 and response to rituximab in RA","volume":"65","author":"Sellam","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib0710","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/annrheumdis-2012-202814","article-title":"Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin","volume":"73","author":"Mathes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.02.016_bib0715","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","article-title":"Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib0720","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.4049\/jimmunol.165.11.6635","article-title":"Quantitative genetic variation in CD19 expression correlates with autoimmunity","volume":"165","author":"Sato","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0725","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/2047-783X-15-1-44","article-title":"Absolute count of T and B lymphocyte subsets is decreased in systemic sclerosis","volume":"15","author":"Gambichler","year":"2010","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.revmed.2016.02.016_bib0730","doi-asserted-by":"crossref","first-page":"148293","DOI":"10.1155\/2014\/148293","article-title":"Association of immunological cell profiles with specific clinical phenotypes of scleroderma disease","volume":"2014","author":"L\u00f3pez-Cacho","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.revmed.2016.02.016_bib0735","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.4049\/jimmunol.0803705","article-title":"Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse","volume":"182","author":"Servettaz","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0740","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI0215078","article-title":"CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse","volume":"109","author":"Saito","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.revmed.2016.02.016_bib0745","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2353\/ajpath.2006.060205","article-title":"B lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis","volume":"169","author":"Hasegawa","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0750","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1182\/blood-2012-11-465658","article-title":"Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease","volume":"121","author":"Le Huu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2016.02.016_bib0755","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/rheumatology\/kev331","article-title":"Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity","volume":"55","author":"Matsushita","year":"2016","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.revmed.2016.02.016_bib0760","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fimmu.2015.00496","article-title":"Systemic Sclerosis patients present alterations in the expression of molecules involved in B cell regulation","volume":"6","author":"Soto","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0765","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/art.39437","article-title":"Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis","volume":"68","author":"Mavropoulos","year":"2016","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.revmed.2016.02.016_bib0770","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1038\/sj.jid.5700919","article-title":"BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice","volume":"127","author":"Matsushita","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0775","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.clim.2013.06.006","article-title":"Aberrant histone modification in peripheral blood B cells from patients with systemic sclerosis","volume":"149","author":"Wang","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0780","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9440(10)63328-7","article-title":"B lymphocyte signaling established by the CD19\/CD22 loop regulates autoimmunity in the tight-skin mouse","volume":"165","author":"Asano","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0785","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.molimm.2004.06.025","article-title":"Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis","volume":"41","author":"Sato","year":"2004","journal-title":"Mol Immunol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0790","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2003-08-2694","article-title":"BAFF\/BLyS can potentiate B cell selection with the B cell coreceptor complex","volume":"103","author":"Hase","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2016.02.016_bib0795","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.20674","article-title":"Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis","volume":"50","author":"Tsuchiya","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib0800","first-page":"839","article-title":"Association study of B cell marker gene polymorphisms in European Caucasian patients with systemic sclerosis","volume":"29","author":"Dawidowicz","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0805","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00296-010-1610-3","article-title":"Serum levels of soluble CD21 in patients with systemic sclerosis","volume":"32","author":"Tomita","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.revmed.2016.02.016_bib0810","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2249.2009.04059.x","article-title":"Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis","volume":"159","author":"Odaka","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0815","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-0039.2007.00801.x","article-title":"Association of CD22 gene polymorphism with susceptibility to limited cutaneous systemic sclerosis","volume":"69","author":"Hitomi","year":"2007","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.revmed.2016.02.016_bib0820","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1002\/art.24885","article-title":"BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4","volume":"60","author":"Dieud\u00e9","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib0825","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2009.118174","article-title":"BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians","volume":"69","author":"Rueda","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.02.016_bib0830","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaut.2009.08.014","article-title":"Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations","volume":"34","author":"Gourh","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.revmed.2016.02.016_bib0835","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/art.27303","article-title":"Association of the FAM167A\u2013BLK region with systemic sclerosis","volume":"62","author":"Ito","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib0840","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.30379","article-title":"C8orf13\u2013BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large French cohort and meta-analysis","volume":"63","author":"Coustet","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib0845","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes","volume":"54","author":"Matsushita","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib0850","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/1756-185x.12019","article-title":"Serum B cell activating factor assessment in a population of Egyptian patients with systemic sclerosis","volume":"16","author":"Abdo","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.revmed.2016.02.016_bib0855","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","author":"Brkic","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.02.016_bib0860","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.autrev.2014.07.003","article-title":"Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity","volume":"13","author":"Lanteri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2016.02.016_bib0865","first-page":"2056","article-title":"Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF","volume":"34","author":"Matsushita","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0870","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.3899\/jrheum.100454","article-title":"Increased production of a proliferation-inducing ligand (APRIL) by peripheral blood mononuclear cells is associated with anti-topoisomerase I antibody and more severe disease in systemic sclerosis","volume":"37","author":"Bielecki","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0875","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jbspin.2010.05.004","article-title":"Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: possible association with myositis?","volume":"78","author":"Bassyouni","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2016.02.016_bib0880","article-title":"Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells","author":"Yoshizaki","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.02.016_bib0885","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/art.38901","article-title":"Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis","volume":"67","author":"Takahashi","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.revmed.2016.02.016_bib0890","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2353\/ajpath.2008.071049","article-title":"CD19 regulates skin and lung fibrosis via toll-like receptor signaling in a model of bleomycin-induced scleroderma","volume":"172","author":"Yoshizaki","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0895","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5021\/ad.2015.27.1.1","article-title":"Abnormal B Lymphocyte activation and function in systemic sclerosis","volume":"27","author":"Yoshizaki","year":"2015","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0900","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/art.38219","article-title":"Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis","volume":"66","author":"Sobanski","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0905","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/ard.56.4.230","article-title":"Assessment of anti-endothelial cell antibodies in systemic sclerosis and Sj\u00f6gren's syndrome","volume":"56","author":"Hebbar","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.02.016_bib0910","first-page":"462","article-title":"Anti-endothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension","volume":"25","author":"Negi","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0915","first-page":"527","article-title":"Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment","volume":"16","author":"Pignone","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0920","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2249.2000.01115.x","article-title":"Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis","volume":"119","author":"Ihn","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0925","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1309\/8HVCMJMYNPUQPBD2","article-title":"The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis","volume":"120","author":"Wusirika","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0930","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/thx.2004.029082","article-title":"Anti-endothelial cell antibodies in idiopathic and systemic sclerosis-associated pulmonary arterial hypertension","volume":"60","author":"Tamby","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.revmed.2016.02.016_bib0935","first-page":"992","article-title":"More severe nailfold capillaroscopy findings and anti-endothelial cell antibodies. Are they useful tools for prognostic use in systemic sclerosis?","volume":"26","author":"Riccieri","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0940","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.2010.135772","article-title":"Involvement of functional autoantibodies against vascular receptors in systemic sclerosis","volume":"70","author":"Riemekasten","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.02.016_bib0945","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","article-title":"Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis","volume":"190","author":"Becker","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2016.02.016_bib0950","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar4503","article-title":"Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients","volume":"16","author":"G\u00fcnther","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2016.02.016_bib0955","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar4457","article-title":"Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis","volume":"16","author":"Kill","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2016.02.016_bib0960","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3899\/jrheum.150061","article-title":"Autoantibodies against endothelin 1 type A receptor are strong predictors of digital ulcers in systemic sclerosis","volume":"42","author":"Avouac","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib0965","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/art.10361","article-title":"Autoantibodies to fibroblasts induce a pro-adhesive and pro-inflammatory fibroblast phenotype in patients with systemic sclerosis","volume":"46","author":"Chizzolini","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib0970","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.10362","article-title":"Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway","volume":"46","author":"Ronda","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib0975","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.06.00152705","article-title":"Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension","volume":"28","author":"Tamby","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2016.02.016_bib0980","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/rheumatology\/kem241","article-title":"Antifibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts","volume":"46","author":"Fineschi","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2016.02.016_bib0985","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1002\/art.24049","article-title":"Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce pro-fibrotic chemokines, with partial exploitation of toll-like receptor 4","volume":"58","author":"Fineschi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib0990","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1164\/rccm.200707-1015OC","article-title":"Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension","volume":"177","author":"Terrier","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2016.02.016_bib0995","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.2008.104299","article-title":"Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease","volume":"69","author":"Terrier","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.02.016_bib1000","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1523-1747.2003.12097.x","article-title":"Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis","volume":"120","author":"Sato","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib1005","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2249.2004.02615.x","article-title":"Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis","volume":"138","author":"Nishijima","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.revmed.2016.02.016_bib1010","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.4049\/jimmunol.163.2.1066","article-title":"Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases","volume":"163","author":"Tan","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.revmed.2016.02.016_bib1015","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/1529-0131(200011)43:11<2464::AID-ANR13>3.0.CO;2-F","article-title":"Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles","volume":"43","author":"Tan","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib1020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000049191","article-title":"Anti-fibrillin-1 autoantibodies in systemic sclerosis are GM and KM allotype-restricted","volume":"18","author":"Pandey","year":"2001","journal-title":"Exp Clin Immunogenet"},{"key":"10.1016\/j.revmed.2016.02.016_bib1025","doi-asserted-by":"crossref","first-page":"R1221","DOI":"10.1186\/ar1813","article-title":"Absence of autoantibodies against correctly folded recombinant fibrillin-1 protein in systemic sclerosis patients","volume":"7","author":"Brinckmann","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2016.02.016_bib1030","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.4049\/jimmunol.175.7.4555","article-title":"Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the \u201cscleroderma phenotype\u201d","volume":"175","author":"Zhou","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.revmed.2016.02.016_bib1035","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.02.016_bib1040","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1136\/ard.2007.085480","article-title":"Anti-PDGFR-alpha antibodies measured by non-bioactivity assays are not specific for systemic sclerosis","volume":"67","author":"Balada","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.02.016_bib1045","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.24381","article-title":"Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis","volume":"60","author":"Classen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib1050","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/art.24365","article-title":"Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor \u03b1 in a subset of normal and systemic sclerosis patient sera","volume":"60","author":"Loizos","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib1055","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/art.39125","article-title":"Epitope specificity determines pathogenicity and detectability of anti-platelet-derived growth factor receptor \u03b1 autoantibodies in systemic sclerosis","volume":"67","author":"Moroncini","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.revmed.2016.02.016_bib1060","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/ard.2007.073387","article-title":"Blockade of CD40\/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse","volume":"67","author":"Komura","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.02.016_bib1065","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature","volume":"14","author":"Giuggioli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2016.02.016_bib1070","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar3907","article-title":"IL-10-producing regulatory B cells (B10 cells) in autoimmune disease","volume":"15","author":"Kalampokis","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2016.02.016_bib1075","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1182\/blood-2014-04-571125","article-title":"Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD","volume":"124","author":"Khoder","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2016.02.016_bib1080","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood-2014-09-599159","article-title":"CD24hiCD27+ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease","volume":"125","author":"de Masson","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2016.02.016_bib1085","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/leu.2014.225","article-title":"Mesenchymal stromal cells infusions improve refractory chronic graft-versus-host disease through an increase of CD5+ regulatory B cells producing interleukin 10","volume":"29","author":"Peng","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2016.02.016_bib1090","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/cyto.2000.0822","article-title":"Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma: extraordinary high level of IL-6 secretion by stimulated fibroblasts","volume":"13","author":"Kondo","year":"2001","journal-title":"Cytokine"},{"key":"10.1016\/j.revmed.2016.02.016_bib1095","doi-asserted-by":"crossref","first-page":"e111266","DOI":"10.1371\/journal.pone.0111266","article-title":"MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts","volume":"9","author":"Alsaleh","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.revmed.2016.02.016_bib1100","doi-asserted-by":"crossref","first-page":"R168","DOI":"10.1186\/ar4352","article-title":"B lymphocytes and B cell activating factor promote collagen and pro-fibrotic markers expression by dermal fibroblasts in systemic sclerosis","volume":"15","author":"Fran\u00e7ois","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2016.02.016_bib1105","doi-asserted-by":"crossref","first-page":"R145","DOI":"10.1186\/ar3879","article-title":"B cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin","volume":"14","author":"Daoussis","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2016.02.016_bib1110","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.revmed.2010.07.015","article-title":"Cytokines and T cell differentiation in systemic sclerosis","volume":"32","author":"Trad","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2016.02.016_bib1115","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.4049\/jimmunol.155.5.2703","article-title":"T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis","volume":"155","author":"Kuwana","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.revmed.2016.02.016_bib1120","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/rheumatology\/kes258","article-title":"Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis","volume":"52","author":"Hasegawa","year":"2013","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.revmed.2016.02.016_bib1125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00403-012-1292-7","article-title":"Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis","volume":"305","author":"Yanaba","year":"2013","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.revmed.2016.02.016_bib1130","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1006\/jaut.1993.1059","article-title":"Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight-skin mice into C57BL\/6Pa\/Pa mice","volume":"6","author":"Phelps","year":"1993","journal-title":"J Autoimmun"},{"key":"10.1016\/j.revmed.2016.02.016_bib1135","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/art.27428","article-title":"Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator\/inducible costimulator ligand pathway","volume":"62","author":"Tanaka","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib1140","first-page":"S228","article-title":"Effects of rituximab therapy on elastic properties of vascular wall in patients with progressive systemic sclerosis","volume":"32","author":"Maslyanskiy","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib1145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/03009742.2013.869617","article-title":"Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases Results of a lower dosage and shorter interval regimen","volume":"43","author":"Moazedi-Fuerst","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib1150","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ced.12450","article-title":"Dosage of rituximab in systemic sclerosis: 2-year results of five cases","volume":"40","author":"Moazedi-Fuerst","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib1155","doi-asserted-by":"crossref","first-page":"e147616","DOI":"10.1155\/2015\/147616","article-title":"Endothelin receptors expressed by immune cells are involved in modulation of inflammation and in fibrosis: relevance to the pathogenesis of systemic sclerosis","volume":"2015","author":"Elisa","year":"2015","journal-title":"J Immunol Res"},{"issue":"Suppl. 4","key":"10.1016\/j.revmed.2016.02.016_bib1160","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.1016\/j.revmed.2007.09.003","article-title":"Treatment of systemic sclerosis (except pulmonary arterial hypertension)","volume":"28","author":"Hachulla","year":"2007","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2016.02.016_bib1165","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","article-title":"Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis","volume":"44","author":"Bosello","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2016.02.016_bib1170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ard.2008.095463","article-title":"Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study","volume":"69","author":"Smith","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.02.016_bib1175","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3899\/jrheum.120778","article-title":"Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement","volume":"40","author":"Smith","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib1180","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib1185","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2016.02.016_bib1190","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood-2014-02-554279","article-title":"Treatment of chronic graft-versus-host disease with bortezomib","volume":"124","author":"Pai","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2016.02.016_bib1195","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.bbmt.2014.06.040","article-title":"A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease","volume":"20","author":"Herrera","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.revmed.2016.02.016_bib1200","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jdermsci.2014.02.008","article-title":"Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease","volume":"74","author":"Le Huu","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.revmed.2016.02.016_bib1205","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1182\/blood-2014-08-595470","article-title":"Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease","volume":"125","author":"Flynn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2016.02.016_bib1210","first-page":"15","article-title":"Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model","volume":"33","author":"Pamuk","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2016.02.016_bib1215","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1172\/JCI75328","article-title":"Ibrutinib treatment ameliorates murine chronic graft-versus-host disease","volume":"124","author":"Dubovsky","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.revmed.2016.02.016_bib1220","doi-asserted-by":"crossref","first-page":"e0137641","DOI":"10.1371\/journal.pone.0137641","article-title":"Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice","volume":"10","author":"Schutt","year":"2015","journal-title":"PLoS One"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866316000849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866316000849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:37:26Z","timestamp":1759336646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866316000849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":122,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0248866316000849"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2016.02.016","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of B cells in the pathogenesis of systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2016.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}